Adapting Eligibility Criteria for Prescribing FDA Approved Anti-amyloid Immunotherapeutics for Adults with Down Syndrome with Early-Stage Alzheimer’s Dementia

An international group of experts convened to determine prescribing criteria equivalences that would be inclusionary…
Kim WarrenJune 2, 2023